Project Details
Description
Protocol AL-108-213: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
| Status | Finished |
|---|---|
| Effective start/end date | 6/1/10 → 5/31/13 |
Funding
- Allon Therapeutics
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.